PharmaShots Weekly Snapshots (November 28 – December 02, 2022)

Share this

PharmaShots Weekly Snapshots (November 28 – December 02, 2022)

Compass Therapeutics Reports the First Patient Dosing of CTX-471 + Keytruda (pembrolizumab) for the Treatment of Advanced Solid Tumors

Published: Dec 02, 2022 | Tags: Compass Therapeutics, CTX-471, Keytruda, pembrolizumab, Advanced Solid Tumors, Clinical Trial

Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022

Published: Dec 02, 2022 | Tags: Qilu Pharmaceutical, QL1706, Non-Small Cell Lung Cancer, Clinical Trial, P-II Study, ESMO, 2022

Rigel’s Rezlidhia (olutasidenib) Receives the US FDA’s Approval for the Treatment of Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Published: Dec 02, 2022 | Tags: Rigel, Rezlidhia, olutasidenib, Acute Myeloid Leukemia, IDH1 Mutation, Regulatory, US, FDA, Approval

UroGen Presents P-III (OLYMPUS) Trial Results of Jelmyto (mitomycin) for the Treatment of Low-Grade Upper Tract Urothelial Cancer at SUO 2022

Published: Dec 02, 2022 | Tags: UroGen, Jelmyto, mitomycin, Low-Grade Upper Tract Urothelial Cancer, Clinical Trial, P-III (OLYMPUS) Trial, SUO, 2022

Anavex Presents P-IIb/III (ANAVEX 2-73-AD-004) Trial Results of ANAVEX 2–73 (blarcamesine) for Early Alzheimer’s Disease at CTAD 2022

Published: Dec 02, 2022 | Tags: Anavex, ANAVEX 2–73, blarcamesine, Early Alzheimer’s Disease, Clinical Trial, P-IIb/III (ANAVEX 2-73-AD-004) Trial, CTAD, 2022

SCYNEXIS’ Brexafemme (ibrexafungerp) Receives the US FDA’s Approval for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Published: Dec 02, 2022 | Tags: SCYNEXIS, Brexafemme, ibrexafungerp, Vulvovaginal Candidiasis, Regulatory, US, FDA, Approval

AbCellera Collaborated with Rallybio to Develop and Commercialize Novel Antibody-Based Therapies for the Treatment of Rare Diseases

Published: Dec 01, 2022 | Tags: AbCellera, Rallybio, Antibody-Based Therapies, Rare Diseases, Ab discovery engine, Pharma

IPA’s Subsidiary BioStrand Entered into a Research Collaboration and License Agreement with BriaCell to Discover and Develop Anti-Cancer Antibodies

Published: Dec 01, 2022 | Tags: IPA, BioStrand, BriaCell, Anti-Cancer Antibodies, LENSai software, HYFT Universal Fingerprint technologies

Liminatus Pharma Entered into a Definitive Business Combination Agreement with Iris to Advance the Cancer Treatment

Published: Dec 01, 2022 | Tags: Liminatus Pharma, Iris, colorectal, pancreatic, gastric, esophageal cancers, M&A

Regeneron Reports the US FDA’s Acceptance of sBLA for Priority Review of Evkeeza (evinacumab) to Treat Homozygous Familial Hypercholesterolemia

Published: Dec 01, 2022 | Tags: Regeneron, Evkeeza, evinacumab, Homozygous Familial Hypercholesterolemia, Regulatory, US, FDA, Acceptance, sBLA, Priority Review

BioNTech Entered into a Multi-Target Research Collaboration with Ryvu Therapeutics to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Published: Dec 01, 2022 | Tags: BioNTech, Ryvu Therapeutics, Immuno-Modulatory Small Molecule Candidates, oncology, Pharma

Eli Lilly Reports P-III (TRAILBLAZER-ALZ 4) Study Results of Donanemab for the Treatment of Early Symptomatic Alzheimer's Disease

Published: Dec 01, 2022 | Tags: Eli Lilly, Donanemab, Early Symptomatic Alzheimer's Disease, Clinical Trial, P-III, TRAILBLAZER-ALZ 4 Study

Eisai and Biogen Publishes Results of P-III Study (Clarity AD) of Lecanemab for Early Alzheimer's Disease

Published: Nov 30, 2022 | Tags: Eisai, Biogen, Lecanemab, Early Alzheimer's Disease, Clinical Trial, P-III, New England Journal of Medicine, Clarity AD

Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the US

Published: Nov 30, 2022 | Tags: Shanghai Henlius Biotech, Hansizhuang, serplulimab, Extensive-Stage Small Cell Lung Cancer Treatment, MSI-H solid tumors, squamous non-small cell lung cancer, Clinical Trial, NMPA, US FDA, NDA

Turnstone Biologics and National Cancer Institute Enters into a R&D Agreement to Study TIL Therapy + Viral Immunotherapy for Solid Tumors

Published: Nov 30, 2022 | Tags: Turnstone Biologics, National Cancer Institute, TIL Therapy, Immunotherapy, Solid Tumors, Pharma

Autobahn Initiates the P-I Trial of ABX-002 for the Treatment of Major Depressive Disorder

Published: Nov 30, 2022 | Tags: Autobahn, ABX-002, Major Depressive Disorder, Clinical Trial, P-I

Aclaris Enters into a License Agreement with Pediatrix for Developing and Commercializing ATI-1777 in Greater China

Published: Nov 30, 2022 | Tags: Aclaris, Pediatrix, ATI-1777, Atopic Dermatitis, Clinical Trials, Greater China

Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer

Published: Nov 30, 2022 | Tags: Immutep, Merck KGaA, Pfizer, Eftilagimod Alpha, Avelumab, Urothelial Cancer, Clinical Trial, Germany, INSIGHT-005, INSIGHT-004

CSL Vifor and Fresenius Kabi Receive the NMPA’s Approval for Ferinject to Treat Iron Deficiency in Adult Patients

Published: Nov 29, 2022 | Tags: CSL Vifor, Fresenius Kabi, Ferinject, Iron Deficiency, Regulatory, NMPA Approval

AstraZeneca to Acquire Neogene Therapeutics for ~$320M

Published: Nov 29, 2022 | Tags: AstraZeneca, Neogene Therapeutics, Acquire, ~$320M, solid tumors

Full-Life Technologies Signed an Agreement to Acquire Focus-X Therapeutics to Advance Peptide-Focused Radiopharmaceutical Pipeline

Published: Nov 29, 2022 | Tags: Full-Life Technologies, Focus-X Therapeutics, Peptide-Focused Radiopharmaceutical Pipeline, pancreatic cancer, metastatic castration resistant prostate cancer, M&A

axsome Therapeutics Reports P-III (ACCORD) Trial Results of AXS-05 for the Treatment of Alzheimer’s Disease Agitation

Published: Nov 29, 2022 | Tags: axsome Therapeutics, AXS-05, Alzheimer’s Disease Agitation, Clinical Trial, P-III, ACCORD Trial

Arcutis Reports P-IIb Study Results of Roflumilast for the Treatment of Plaque Psoriasis

Published: Nov 29, 2022 | Tags: Arcutis, Roflumilast Cream, Plaque Psoriasis, Clinical Trial, P-IIb Study

Biocytogen Enters into Evaluation and Option Agreement with ADC Therapeutics for Antibody-Based Therapies

Published: Nov 29, 2022 | Tags: Biocytogen, ADC Therapeutics, Antibody-Based Therapies, Project Integrum, RenMice HiTS Platform, Option Agreement, Biotech

RadNet AI Subsidiary Aidence Collaborated with Google Health to Improve Lung Cancer Screening Using AI Solutions

Published: Nov 28, 2022 | Tags: RadNet, Aidence, Google Health, Lung Cancer, AI Solutions, NELSON trial, Pharma

AstraZeneca Signed ~$402M Exclusive Worldwide License Agreement with C4XD to Develop and Commercialize NRF2 Activator Program

Published: Nov 28, 2022 | Tags: AstraZeneca, C4XD, NRF2 Activator Program, Pharma

GSK Submits Respiratory Syncytial Virus Vaccine for Regulatory Review to Health Canada

Published: Nov 28, 2022 | Tags: GSK, Respiratory Syncytial Virus Vaccine, Regulatory Review, Health Canada, Clinical Trial

Edwards Presents (TRISCEND) Study Results of EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation at PCR 2022

Published: Nov 28, 2022 | Tags: Edwards, EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement, Tricuspid Regurgitation, Clinical Trial, TRISCEND Study

Lyvgen Entered into a Clinical Collaboration with BMS to Evaluate LVGN7409 + Nivolumab for Non-Small Cell Lung Cancer

Published: Nov 28, 2022 | Tags: Lyvgen, BMS, LVGN7409, Nivolumab, Non-Small Cell Lung Cancer, Pharma

BMS’ Opdivo (nivolumab) Receives NICE Recommendation as 1L Treatment for Rare Gastroesophageal Cancers

Published: Nov 28, 2022 | Tags: BMS, Opdivo, nivolumab, Gastroesophageal Cancers, Regulatory, NICE

Related Post: PharmaShots Weekly Snapshots (November 21 - 25, 2022)

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions